

# Paula Iruzubieta

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2143797/paula-iruzubieta-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42  
papers

513  
citations

14  
h-index

21  
g-index

48  
ext. papers

811  
ext. citations

5.8  
avg. IF

3.66  
L-index

#	Paper	IF	Citations
42	Vitamin D deficiency in chronic liver disease. <i>World Journal of Hepatology</i> , <b>2014</b> , 6, 901-15	3.4	63
41	The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. <i>Nature Communications</i> , <b>2017</b> , 8, 2068	17.4	45
40	Long-term survival after liver transplantation for alcoholic liver disease. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 9198-208	5.6	42
39	Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. <i>Nature Communications</i> , <b>2020</b> , 11, 3360	17.4	34
38	Hepatic p63 regulates steatosis via IKK $\beta$ /ER stress. <i>Nature Communications</i> , <b>2017</b> , 8, 15111	17.4	32
37	LOXL2-A New Target in Antifibrogenic Therapy?. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	31
36	Deregulated neddylation in liver fibrosis. <i>Hepatology</i> , <b>2017</b> , 65, 694-709	11.2	28
35	Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. <i>Cell Metabolism</i> , <b>2020</b> , 31, 605-622.e10	24.6	24
34	Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 469-471	13.4	23
33	A morphological method for ammonia detection in liver. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173914	3.7	18
32	miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. <i>Molecular Metabolism</i> , <b>2019</b> , 29, 40-54	8.8	17
31	Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	17
30	The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?. <i>BioMed Research International</i> , <b>2015</b> , 2015, 386186	3	15
29	Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2018</b> , 1864, 3655-3667	6.9	15
28	Metabolic effects of reduced growth hormone action in fatty liver disease. <i>Hepatology International</i> , <b>2018</b> , 12, 474-481	8.8	14
27	Plasma betatrophin levels in patients with liver cirrhosis. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 10662-8	5.6	12
26	A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	10

25	E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. <i>Cancer Research</i> , <b>2021</b> , 81, 2874-2887	10.1	10
24	Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 95-103	3.3	8
23	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 1627-1633 <sup>8</sup>	4.1	8
22	Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. <i>Cells</i> , <b>2019</b> , 8,	7.9	7
21	SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 966-967	13.4	7
20	Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 34-45	13.4	4
19	Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	3
18	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 892-902	5.3	3
17	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease <b>2018</b> ,		3
16	Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. <i>World Journal of Clinical Cases</i> , <b>2018</b> , 6, 611-623	1.6	2
15	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. <i>Molecular Metabolism</i> , <b>2021</b> , 53, 101275	8.8	2
14	Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles.. <i>Hepatology</i> , <b>2022</b> ,	11.2	2
13	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.. <i>Biomedicines</i> , <b>2021</b> , 10,	4.8	2
12	Resistance to hepatitis C virus. Implications and therapeutic options. <i>Gastroenterología Y Hepatología</i> , <b>2017</b> , 40, 484-494	0.9	1
11	Biochemical assessment of metabolic associated fatty liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , <b>2021</b> , 2, 199-208	1.3	1
10	Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFN $\gamma$ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells. <i>Viruses</i> , <b>2021</b> , 13,	6.2	1
9	Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. <i>Scientific Reports</i> , <b>2021</b> , 11, 9819	4.9	1
8	Measurement and clinical usefulness of bilirubin in liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , <b>2021</b> , 2, 352-361	1.3	1

7	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	1
6	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. <i>JHEP Reports</i> , <b>2021</b> , 3, 100276	10.3	0
5	Let's leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 224-226	13.4	0
4	National digestive disease specialists survey on cardiovascular risk management in non-alcoholic fatty liver disease in spanish hospitals. <i>Liver International</i> , <b>2021</b> , 41, 1243-1253	7.9	0
3	Can NAFLD overwhelm the Spanish healthcare system in the years to come?. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2021</b> , 114, 5-9	0.9	
2	Bilirrubina: Medici3n y utilidad cl3nica en la enfermedad hep3tica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , <b>2021</b> , 2, 362-372	1.3	
1	Valoraci3n bioqu3mica en la enfermedad hep3tica grasa asociada a la disfunci3n metab3lica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , <b>2021</b> , 2, 209-219	1.3	